Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer
No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease
Objective response seen in 37.1 percent of patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer
Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer
Efficacy data revealed 40 percent response rate, median response duration of 11.1 months
<p style="margin-left: 20px;">Progression-free survival significantly longer with tislelizumab plus chemotherapy versus chemotherapy alone
Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i<strong></strong>
Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib
Guidelines reduce postoperative opioid prescribing but may result in inadequate pain control for some